At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed metastatic NSCLC or stage III not candidates for surgery/chemoradiation
- ✓EGFR and ALK mutation-negative disease
- ✓PD-L1 TPS ≥50% or lower with prior single agent pembrolizumab per guidelines
- ✓Screening ctDNA drawn after registration, within 2 cycles of Q3W or 1 cycle of Q6W pembrolizumab
- ✕Large Cell Neuroendocrine Carcinoma (LCNEC)
- ✕Symptomatic CNS metastases or CNS metastases requiring immunosuppressive corticosteroids >10 mg/day prednisone equivalents
- ✕Not suitable candidates for pembrolizumab per Product Monograph/Drug Label including active infection, autoimmune disease, immunosuppressive therapy requirements, severe immune-mediated adverse reactions, hypersensitivity
- ✕Contraindications to platinum combination chemotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Lung Cancer. Currently recruiting, targeting 230 participants across 11 sites in 2 countries.
Signals
Detailed Summary
The standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV). Some cancers shed DNA (circulating tumour DNA or ctDNA) or genes (biomarkers) into the blood, and levels of these biomarkers may be able to tell researchers how people respond to treatment with pembrolizumab before they feel worse, or the cancer is worse on imaging tests. Researchers are studying how levels of these biomarkers can show how cancers are responding to treatment and whether adding chemotherapy to pembrolizumab based on detection of ctDNA can offer better results.
Study Details
Timeline
Arms & Interventions
Interventions
Per current Product Monograph/U.S. Drug Label and/or local guidelines.